[S-8] Fenbo Holdings Limited Employee Benefit Plan Registration

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE’s common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June – 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE’s ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company’s underlying fundamentals.

Positive

• Regained Nasdaq compliance under Rule 5550(a)(2), removing imminent delisting risk.
• Improved liquidity and investor perception by maintaining national exchange status.

Negative

• Share-price fragility remains; any fall below $1.00 could renew deficiency.
• Event does not address operational fundamentals or cash needs.

Insights

Securities Analyst

TL;DR: Nasdaq closes delisting threat; liquidity and investor confidence improve, but price must stay above $1.

The lift of the bid-price deficiency is materially positive for SNSE as it removes a technical overhang that can suppress trading volumes and deter institutional holders. Retention of Nasdaq listing preserves access to capital markets and potential inclusion in small-cap indices. The event does not address core clinical or cash-runway challenges; share price stability remains the key variable. Overall, the action is modestly accretive to sentiment rather than fundamentals.

Corporate Governance Expert

TL;DR: Compliance restored, governance risk lowered; vigilance required to prevent future bid-price breaches.

Regained compliance signals effective board oversight in resolving exchange deficiencies, minimizing reputational and governance risk. Continued adherence will require proactive investor-relations outreach and potential corporate actions (reverse split, capital raise) if market pressure resurfaces. No changes to control structure or reporting obligations were disclosed.

As filed with the Securities and Exchange Commission on July 9, 2025

Registration No. : 001-41873

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Fenbo Holdings Limited

(Exact name of registrant as specified in its charter)

Cayman		N/A
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Unit J, 19/F, World Tech Centre

95 How Ming Street

Kwun Tong

Kowloon, Hong Kong

+(852) 2343 3328

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

FENBO HOLDINGS LIMITED

2025 EQUITY INCENTIVE PLAN

(Full title of the plans)

Henry F. Schlueter, Esq.

Schlueter & Associates, P.C.

5655 South Yosemite St., Suite 350

Greenwood, Village, Colorado 80111

(303) 292-3883

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Item 1. Plan Information 

Fenbo Holdings Limited (the “Company”) has adopted the Fenbo Holdings Limited 2025 Equity Incentive Plan (“Plan”). The maximum number of ordinary shares of the Company of a par value of US$0.0001 each (the “Ordinary Shares”) that are available for issuance under the Plan is an aggregate of 2,200,000 Ordinary Shares. This Registration Statement on Form S-8 is filed with the Securities and Exchange Commission (“Commission”) for the purposes of registering the 2,200,000 Ordinary Shares issuable under the Plan.

Item 2. Registrant Information and Employee Plan Annual Information 

The documents containing the information specified in this Part I of Form S-8 (plan information and registration information) will be sent or given to employees as specified by the Securities and Exchange Commission pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be and are not filed with the Commission either as part of this registration statement (this “Registration Statement”) or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. The Registrant will provide a written statement to participants advising them of the availability without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge, upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b), and will include the address and telephone number to which the request is to be directed.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents previously filed by Fenbo Holdings Limited (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) are incorporated by reference herein:

(a)	Our Annual Reports on Form 20-F for the fiscal years ended December 31, 2023 and 2024, filed with the SEC on April 29, 2024 and May 14, 2025, respectively;
(b)	Our Current Reports on Form 6-K filed with the SEC on April 29, 2025, March 25, 2025, January 24, 2025, December 16, 2024, December 6, 2024, October 3, 2024, September 3, 2024, January 19, 2024, and December 7, 2023;
(c)	The description of the Registrant’s Ordinary Shares: (i) set forth in our Registration Statement on Form F-1 filed with the SEC on September 11, 2023 in the section entitled “Description of Securities”; (ii) set forth in Exhibit No. 2.1 to our Annual Report on Form 20-F filed with the SEC on April 29, 2024; and (iii) incorporated by reference in the Registrant’s registration statement on 8-A File No. 001-41973) filed with the Commission on November 20, 2023, including any amendment and report subsequently filed for the purpose of updating that description;
(e)	all reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the report referred to in (a) above.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents. Any statement in a document incorporated or deemed to be incorporated by reference in this registration statement will be deemed to be modified or superseded to the extent that a statement contained in this registration statement or in any other later filed document that also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as so modified or superseded, to be a part of this registration statement.

Item 4. Description of Securities.

Not applicable

Item 5. Interests of Named Experts and Counsel.

Not applicable

Item 6. Indemnification of Directors and Officers.

Cayman Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. The Registrant’s amended and restated memorandum and articles of association provide that that it shall indemnify its directors and officers, and their personal representatives, against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such persons, other than by reason of such person’s dishonesty, willful default or fraud, in or about the conduct of the Registrant’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

In addition, the Registrant has entered into indemnification agreements with its directors and executive officers that provide such persons with additional indemnification beyond that provided in the Registrant’s amended and restated memorandum and articles of association.

Indemnification against Public Policy

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant’s directors, officers or person controlling us, the Registrant has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

The following exhibits are filed as part of this Registration Statement:

Exhibit Number		Description of Document
5.1*		Opinion of Harney Westwood & Riegels with respect to the legality of the securities being registered
10.1*		Fenbo Holdings Limited 2025 Equity Incentive Plan  .
23.1*		Consent of SR CPA & Co., an independent registered public accounting firm.
24.1*		Power of Attorney of the directors of the Registrant (contained in the signature pages hereto).
107*		Filing Fee Table.

* Filed herewith.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this Registration Statement which shall include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby further undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Kowloon, Hong Kong on July 9, 2025.

Fenbo Holdings Limited
By:	/s/ Huang Hongwu
Name:	Huang Hongwu
Title:	Chief Executive Officer, President, Chief Operating Officer, Executive Director and Chairman of the Board of Directors

Each of the undersigned members of the board of directors of the Registrant, hereby severally constitutes and appoints Huang Hongwu as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any subsequent registration statements pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Date: July 9, 2025

/s/ Huang Hongwu

Huang Hongwu

Chief Executive Officer, President, Chief Operating Officer, Executive Director and Chairman of the Board of Directors

Date: July 9,2025

/s/ Li Siu Lun Allan

Li Siu Lun Allan

Executive Director

Date: July 9,2025

/s/ Wang Xuefei

Wang Xuefei

Chief Financial Officer, Treasurer, Secretary and Executive Director

Date: July 9,2025

/s/ Wang Zhiyong

Wang Zhiyong

Independent Director

Date: July 9,2025

/s/ Wu Qiuxia

Wu Qiuxia

Independent Director

Date: July 9,2025

/s/ Zhang Peng

Zhang Peng

Independent Director

Date: July 9, 2025

/s/ Dai Lei

Dai Lei

Independent Director

Signature of Authorized U.S. Representative of Registrant

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Fenbo Holdings Limited has signed this Registration Statement on July 9, 2025.

Schlueter & Associates, P.C.
By:	/s/ Henry F. Schlueter
Name:	Henry F. Schlueter

FAQ

Why did Sensei Biotherapeutics (SNSE) file this Form 8-K?

To disclose that Nasdaq confirmed SNSE has regained compliance with the $1.00 minimum bid-price rule.

What is Nasdaq Listing Rule 5550(a)(2)?

It requires a company’s common stock to maintain a minimum closing bid price of $1.00 for continued listing on the Nasdaq Capital Market.

How did SNSE regain compliance?

SNSE’s shares closed at or above $1.00 for 10 consecutive business days (17 Jun–1 Jul 2025), satisfying Nasdaq’s cure criteria.

Does this filing affect SNSE’s financial outlook?

No financial metrics were disclosed; the filing solely addresses listing status, not operational performance.

Could SNSE face delisting again?

Yes. If the bid price falls below $1.00 for 30 consecutive business days, Nasdaq may issue a new deficiency notice.